8-K
filed May 17, 2023, 7:59 PM ET
ticker AUPH
CIK 0001600620
other material
confidence high
sentiment negative
materiality 0.15
Aurinia shareholders reject say-on-pay, equity plan; two directors resign after low support
Aurinia Pharmaceuticals Inc.
- Directors Milne and Hagan received less than majority support; resignations submitted per Majority Voting Policy; board to decide.
- Non-binding say-on-pay failed: 26.85M for, 42.75M against, plus 20.02M broker non-votes.
- Equity Incentive Plan amendment not approved: 30.71M for, 39.15M against, plus 20.02M broker non-votes.
- PricewaterhouseCoopers appointed auditor with 79.86M for, 6.86M against.
- All eight director nominees elected but Milne and Hagan had lower support; others had 40-44M votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aurinia Pharmaceuticals Inc. shareholders rejected Non-binding advisory vote on executive compensation (say on pay) at the 2023-05-17 meeting.
- Proposal
- say on pay
- Outcome
- failed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 3: Based upon the following votes, the shareholders did not approve on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aurinia Pharmaceuticals Inc. shareholders rejected Approval of Amendment to the Equity Incentive Plan at the 2023-05-17 meeting.
- Proposal
- equity plan
- Outcome
- failed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 4: Based upon the following votes, the shareholders did not approve the Company's Amendment to the Equity Incentive Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aurinia Pharmaceuticals Inc. shareholders approved Election of Directors at the 2023-05-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 1: Based upon the following votes, the shareholders elected Dr. George Milne, Mr. Peter Greenleaf, Dr. David R.W. Jayne, Mr. Joseph P. Hagan, Dr. Daniel Billen, Mr. R. Hector MacKay-Dunn, Ms. Jill Leversage, and Dr. Brinda Balakrishnan to serve as members of the Company's board of directors until the annual general meeting of shareholders to be held in 2024.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aurinia Pharmaceuticals Inc. shareholders approved Ratification of Appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm at the 2023-05-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2024 or until a successor is appointed.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.